PBIO earnings

Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe

Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest

Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi

Investor Call Scheduled for Tuesday, August 22, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / August 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the second quarter ended June 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q2 2023 vs. Q2 2022 (rounded to nearest hundred

Validated Nanoemulsion Capabilities Are Transformative Across Multiple Major Markets, New $1.5M Contract, New Manufacturing Facility, and Reduced Cash Burn Set Stage for Expected Strong FY 2023Investor Call Scheduled for Tuesday May 16, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / May 16, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leader in the development and sale of broadly enabling, high pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food & beverage, and other industries, today reported that record quarterly financial results for any fiscal quarter was achieved

Company Pivots Strongly into Revolutionary UltraShear Platform, Achieving Measurable Progress and Traction, Including Expected Record Revenue in Q1 2023Investor Call Scheduled for Tuesday, April 18, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / April 14, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.F

Conference Call Scheduled for Tuesday, April 18 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / April 13, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fiscal Year 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, April 18, 2023. Time: 4:30 PM Eastern Time (ET).To attend this teleconfer

Resources Continue to Pivot to UST Platform Commercialization, Achieving Major Progress and Traction; Revolutionary Nanoemulsions Technology Expected to Drive Major Growth to Profitability in 2023Investor Call Scheduled for Tuesday, November 22, 2022 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 22, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food & beverage industries, today reported financial results for the

Conference Call Scheduled for Tuesday November 22 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 22, 2022. Time: 4:30 PM Eastern Time (ET).To attend this

Canopy CBD Farms, with Multiple Sales Channels and Industry Contacts Nationwide, Partners with PBI to Commercialize Revolutionary Hemp-Derived CBD Product, Offering Unparalleled Topical EffectivenessSOUTH EASTON, MA / ACCESSWIRE / August 18, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide nutraceuticals, biotechnology, cosmetics, and food & beverage industries, today announced the execution of a manufacturing, sales, and distribution agreement with Canopy CBD Farms, LLC ("CCF"), a Massachusetts licensed processor/manufactu

Conference Call Scheduled for Thursday August 18 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / August 16, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Thursday, August 18, 2022. Time: 4:30 PM Eastern Time (ET).To attend this tel

Focused on the Successful Launch of its "Early Access Program" for the UST Platform, Company Already Negotiating with Four Potential Customers for Nanoemulsion Processing in Nutraceuticals and CosmeticsInvestor Call Scheduled for Thursday, May 19, 2022 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / May 19, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today reported financial results for the first quarter ended March 3

Q4 and FY2021 Total Revenue Increased 91% and 64% Respectfully Over Same Periods in 2020;PCT, BaroFold, and PBI Agrochem Groups Scored Important Gains in 2021;UST Platform Achieved Critical 2021 Goals - Discussions Ongoing with Key Leaders in Multiple MarketsInvestor Conference Call Scheduled for Tuesday April 5 at 4:30 PM ETSOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotherapeutics, nutraceuticals, cosmetics, agrochem, food & beverage, and other industries, today announced financial

Conference Call Scheduled for Tuesday, April 5 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / April 1, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2021 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, April 5, 2022. Time: 4:30 PM Eastern Time (ET).To attend

Operational and Technical Achievements Set Stage for Expected Major Growth and Profitability in 2022Investor Call Scheduled for Wednesday, November 17, 2021 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 17, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2021, provided a business update, and offered guidance for an expected strong 202

Significant Growth Reported in Total Revenue (127%), Instrument Sales (178%), and BaroFold/UST Services (298%); Significant Decrease in Operating Loss (51%) AchievedInvestor Call Scheduled for Thursday, August 19, 2021 at 4:30 p.m. EDTSOUTH EASTON, MA / ACCESSWIRE / August 19, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today reported continued strong financial results for the second quarter ended June 30, 2021, p